Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+Status

被引:16
|
作者
Lu, Hecheng [1 ,2 ]
Yin, Jiandong [2 ]
机构
[1] Northeastern Univ, Sch Med & Bioinformat Engn, Shenyang, Peoples R China
[2] China Med Univ, ShengJing Hosp, Dept Radiol, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
breast cancer; receiver operating characteristic; immunohistochemistry; magnetic resonance imaging; gene expression; IN-SITU HYBRIDIZATION; CONTRAST-ENHANCED MRI; NEOADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; MOLECULAR SUBTYPES; FEATURE-SELECTION; CANCER; HETEROGENEITY; EXPRESSION; FEATURES;
D O I
10.3389/fonc.2020.00543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast tumor heterogeneity is related to risk factors that lead to aggressive tumor growth; however, such heterogeneity has not been thoroughly investigated. Purpose: To evaluate the performance of texture features extracted from heterogeneity subregions on subtraction MRI images for identifying human epidermal growth factor receptor 2 (HER2) 2+ status of breast cancers. Materials and Methods: Seventy-six patients with HER2 2+ breast cancer who underwent dynamic contrast-enhanced magnetic resonance imaging were enrolled, including 42 HER2 positive and 34 negative cases confirmed by fluorescence in situ hybridization. The lesion area was delineated semi-automatically on the subtraction MRI images at the second, fourth, and sixth phases (P-1, P-2, and P-3). A regionalization method was used to segment the lesion area into three subregions (rapid, medium, and slow) according to peak arrival time of the contrast agent. We extracted 488 texture features from the whole lesion area and three subregions independently. Wrapper, least absolute shrinkage and selection operator (LASSO), and stepwise methods were used to identify the optimal feature subsets. Univariate analysis was performed as well as support vector machine (SVM) with a leave-one-out-based cross-validation method. The area under the receiver operating characteristic curve (AUC) was calculated to evaluate the performance of the classifiers. Results: In univariate analysis, the variance from medium subregion at P-2 was the best-performing feature for distinguishing HER2 2+ status (AUC = 0.836); for the whole lesion region, the variance at P-2 achieved the best performance (AUC = 0.798). There was no significant difference between the two methods (P = 0.271). In the machine learning with SVM, the best performance (AUC = 0.929) was achieved with LASSO from rapid subregion at P-2; for the whole region, the highest AUC value was 0.847 obtained at P-2 with LASSO. The difference was significant between the two methods (P = 0.021). Conclusion: The texture analysis of heterogeneity subregions based on intratumoral regionalization method showed potential value for recognizing HER2 2+ status in breast cancer.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Machine learning for predicting breast-conserving surgery candidates after neoadjuvant chemotherapy based on DCE-MRI
    Chen, Zhigeng
    Huang, Manxia
    Lyu, Jianbo
    Qi, Xin
    He, Fengtai
    Li, Xiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [23] Radiomics nomogram for predicting axillary lymph node metastasis in breast cancer based on DCE-MRI: A multicenter study
    Zhang, Jiwen
    Zhang, Zhongsheng
    Mao, Ning
    Zhang, Haicheng
    Gao, Jing
    Wang, Bin
    Ren, Jianlin
    Liu, Xin
    Zhang, Binyue
    Dou, Tingyao
    Li, Wenjuan
    Wang, Yanhong
    Jia, Hongyan
    JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY, 2023, 31 (02) : 247 - 263
  • [24] Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
    Palm, Christiane
    Connolly, Catherine E. E.
    Masser, Regina
    Sgier, Barbara Padberg
    Karamitopoulou, Eva
    Simon, Quentin
    Bode, Beata
    Tinguely, Marianne
    DIAGNOSTICS, 2023, 13 (01)
  • [25] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [26] Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer
    Zeng, Qiao
    Xiong, Fei
    Liu, Lan
    Zhong, Linhua
    Cai, Fengqin
    Zeng, Xianjun
    ACADEMIC RADIOLOGY, 2023, 30 : S38 - S49
  • [27] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
    Ahn, Soomin
    Woo, Ji Won
    Lee, Kyoungyul
    Park, So Yeon
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2020, 54 (01) : 34 - 44
  • [28] HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
    Shafi, Saba
    Nitta, Hiroaki
    Shah, Manan
    Challa, Bindu
    Parwani, Anil, V
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 159 (05) : 464 - 473
  • [29] Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
    Brunelli, Matteo
    Manfrin, Erminia
    Martignoni, Guido
    Miller, Keith
    Remo, Andrea
    Reghellin, Daniela
    Bersani, Samantha
    Gobbo, Stefano
    Eccher, Albino
    Chilosi, Marco
    Bonetti, Franco
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (05) : 678 - 682
  • [30] Principal Component Analysis of Breast DCE-MRI Adjusted With a Model-Based Method
    Eyal, Erez
    Badikhi, Daria
    Furman-Haran, Edna
    Kelcz, Fredrick
    Kirshenbaum, Kevin J.
    Degani, Hadassa
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2009, 30 (05) : 989 - 998